Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $20.89 Consensus Price Target from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned a consensus rating of “Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $20.89.

A number of equities research analysts recently commented on YMAB shares. HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Wednesday, December 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Wedbush restated an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Oppenheimer began coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target for the company. Finally, Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price target on the stock.

Y-mAbs Therapeutics Trading Down 3.4 %

Shares of NASDAQ YMAB opened at $8.28 on Monday. The stock has a market capitalization of $370.85 million, a PE ratio of -15.33 and a beta of 0.61. Y-mAbs Therapeutics has a 12-month low of $6.10 and a 12-month high of $20.90. The stock’s fifty day simple moving average is $12.48 and its two-hundred day simple moving average is $12.59.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter last year, the firm earned ($0.18) EPS. On average, equities analysts predict that Y-mAbs Therapeutics will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. purchased a new position in Y-mAbs Therapeutics during the 3rd quarter worth approximately $267,000. Barclays PLC raised its holdings in shares of Y-mAbs Therapeutics by 433.4% during the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock worth $910,000 after purchasing an additional 56,244 shares during the last quarter. Empire Financial Management Company LLC acquired a new position in Y-mAbs Therapeutics during the third quarter valued at $210,000. Geode Capital Management LLC boosted its holdings in Y-mAbs Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after purchasing an additional 47,846 shares during the last quarter. Finally, State Street Corp grew its position in Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after purchasing an additional 405,169 shares during the period. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.